HER2 Support Group Forums - Inflammatory Breast Cancer Clinical Trial for Her2 positive patients

This is from ibcresearch.org.

This month we want to bring to your attention an international clinical trial specifically for inflammatory breast cancer. While there are limited sites in the U.S. still recruiting, the study started in 2007, it is important that adequate numbers accrue to the trial so the value of the new compound, pazopanib, can be evaluated. Clinical trial data is essential if there is to be evidenced based data to guide treatment of inflammatory breast cancer.

Pazopanib Plus Lapatinib Compared to Lapatinib Alone in Subjects with Inflammatory Breast Cancer is a phase III, double blind trial. A phase III trial is designed to study safety and efficacy. "The double blind part of the study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone in subjects with inflammatory breast cancer whose tumorsoverexpress the ErbB2 protein (Her2/neu). There is also an Open-label pazopanib arm to this study designed to test whether pazopanib given alone and lapatinib given alone would be safe and effective to treat patients with inflammatory breast cancer."
Currently there are just two sites in the U.S. recruiting for the trial, and an additional site is pending. To study the inclusion/exclusion criteria and available sites for this trial (NCT00558102) visit: ClinicalTrials.gov.

**The above is informational only and should not be considered a recommendation or endorsement of any specific clinical trial by the Inflammatory Breast Cancer Research Foundation.